INS and Impaired glucose tolerance: Since higher doses of CsA are associated with impaired glucose tolerance, decreased insulin content, and a decreased β-cell volume [10], we speculated that combining localized CsA microparticles with other immunomodulatory delivery modalities (i.e., CTLA4-Ig) would potentiate allograft protection.